Elizabeth Hexner, MD, MSTR

Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Elizabeth Hexner, MD, MSTR
Penn Medicine Provider

About me

  • Medical Director, Center for Cellular Immunotherapies
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: Columbia University
  • Residency: NewYork-Presbyterian/Columbia University Medical Center
  • Fellowship: University of Pennsylvania Health System

Reviews

Average Rating

378 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
very knowledgeable and excellent communicator
Anonymous
May 2026
very professional and knowledgeable
Anonymous
April 2026
patient
Anonymous
April 2026
kind, answers questions, provides good information and explanations.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Hexner is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Xu, J., McCoy, M., Martinez, Z., Sussman, J. H., Gao, D., Vincent, T. L., Wang, H., Ma, C., Elghawy, O., Chen, G. M., Yang, A. G., Polonen, P., Natan, K., Shraim, R., Newman, H., Hofmann, T. J., Scoma, S., DiNofia, A. M., Hunger, S. P., Yang, J. J., Mullighan, C. G., Bernt, K. M., Hexner, E. O., Grupp, S. A., Watanabe, K., June, C. H., Tan, K., Teachey, D. T., Diorio, C. CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia , Blood Adv, 10(8): 2026,2676-2686


Louloudis, I. E., Chen, Y. B., Spyrou, N., Alousi, A., Katsivelos, N., Ayuk, F., Weber, D., Hogan, W. J., Etra, A. M., Qayed, M., Aguayo-Hiraldo, P., Akahoshi, Y., Malki, M. M. A., Bolanos-Meade, J., Chanswangphuwana, C., Diniz, M., Eder, M., Hexner, E., Kitko, C. L., Kraus, S., Merli, P., Olson, T., MacMillan, M. L., Pidala, J., Reshef, R., Schechter, T., Wolfl, M., Baez, J., Eng, G., Gleich, S., Young, R., Nakamura, R., Ferrara, J. L. M., Levine, J. E. Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity , Transplant Cell Ther, 32(1): 2026,63 e1-63 e11


Gotlib, J., Reiter, A., Radia, D. H., Alvarez-Twose, I., Deininger, M. W., George, T. I., Panse, J. P., Mital, A., Pettit, K. M., Vannucchi, A. M., Platzbecker, U., Hermine, O., Elshoury, A., Livideanu, C., Mesa, R. A., Ustun, C., Triggiani, M., Dybedal, I., Jurcic, J. G., Zanotti, R., Oh, S. T., Yacoub, A., Hexner, E. O., Bose, P., Lee, S. G., Sperr, W. R., Griffiths, E. A., Butler, M., Lubke, J., Bidollari, I., Lin, H. M., Rylova, S. N., Dimitrijevic, S., Munoz-Gonzalez, J. I., DeAngelo, D. J. Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study , Blood Adv, 10(10): 2026,3676-3689


Deng, M. Z., Sinha, T., Lai, M., Jiang, S., Kong, H., Cooper, V., Gu, M., Perelman, J., Zhang, C., Hanindya, C., Carpio, V., Keller, P., Jadlowsky, J. K., Leskowitz, R., McKenna, S., Four, M., Barranco, J. A. J., Cooper, N., Jain, A., Haines, K., Gohil, M., Garcia-Gerique, L., Russell, A., Kulikovskaya, I., Gonzalez, V., Fraietta, J. A., Plesa, G., Sheppard, N. C., Davis, M. M., Chew, A., Hexner, E., Frey, N., June, C. H., Svoboda, J., Riley, J. L. Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells , Res Sq: 2026,rs.3.rs-8436008.


Chen, G. M., Jain, A., Gering, D. T., Satulovsky, J., Datta, S., Lai, P., Karar, J., Gonzalez, V. E., Alexander, K., Chew, A., Jadlowsky, J. K., Ruella, M., Paruzzo, L., Amses, K. R., Rech, A. J., Stadtmauer, E. A., Frey, N. V., Hexner, E. O., Porter, D. L., Cohen, A. D., Gill, S. I., Garfall, A. L., Schuster, S. J., Mo, K. C., Liang, S. I., Spasic, M., Levine, B. L., Siegel, D. L., Ramirez-Fernandez, A., Cabanski, C. R., Yang, E., Mackall, C. L., Bushman, F. D., Good, Z., John Wherry, E., June, C. H., Fraietta, J. A. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer , Nat Biomed Eng, 10(4): 2026,803-814


Barber-Rotenberg, J. S., Haas, A. R., Aggarwal, C., O'Hara, M., Hexner, E., Pequignot, E., Dowd, E., Ndeupen, S., Thai, E., Chen, F., Oner, B. S., Czuczman, C., Gonzalez, V. E., Fraietta, J. A., Hwang, W. T., Chew, A., Jadlowsky, J. K., Marshall, A., Shea, K. M., Jiang, Y., Cosey, A., Ferthio, R., Levine, B. L., Plesa, G., Siegel, D. L., Young, R. M., Sheppard, N. C., Albelda, S. M., June, C. H., Tanyi, J. L. Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers , Mol Ther, 34(5): 2026,2653-2665


Salit RB, Hexner EO, Gagelmann N, Kröger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus , Leukemia, 39(12): 2025,2862-2865


Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang WT, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O'Hara MH Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer , Cell Rep Med, 6(9): 2025,102301.


Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, Park J, Jarocha D, Martins R, Sarmiento N, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz RM, Jadlowsky JK, Mackey S, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Barrett D, Colbourn R, Nasrallah MP, Mourelatos Z, Hwang WT, Alanio C, Siegel DL, June CH, Hexner EO, Binder ZA, O'Rourke DM. Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial , Nat Med, 31(9): 2025,3205


Akahoshi Y, Inamoto Y, Spyrou N, Nakasone H, Diniz M, Asada N, Ayuk FA, Choe HK, Doki N, Eto T, Etra AM, Hexner EO, Hiramoto N, Hogan WJ, Holler EPDm, Kataoka K, Kawakita T, Tanaka M, Tanaka T, Uchida N, Vasova I, Yoshihara S, Ishimaru F, Fukuda T, Chen YB, Kanda J, Nakamura R, Atsuta Y, Ferrara JLM, Kanda Y, Levine JE, Teshima T. Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC , Blood Adv. , 9(18): 2025,4640-4653.